

Our ref: IG/FOI/23.R.230

19 July 2023

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 10 July 2023, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require.

For ease of reference your request is set out below and our response follows:

Your Freedom of Information (FOI) Request:

I am researching the incidence and treatment of oesophageal and gastric cancer. I would greatly appreciate if you could answer the following questions.

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin)
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
- Lonsurf (Trifluridine - tipiracil)
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- Nivolumab monotherapy or combination with Ipilimumab

- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Q3. How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with:

- Nivolumab monotherapy or combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Q4. In the past 3 months, how many patients have been initiated* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer:

- Nivolumab monotherapy or in combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q5. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.

Q6. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.

Powys Response:

Powys Teaching Health Board does not initiate treatment with any of the medication listed; our registered patients are treated by providers outside of Powys.

Powys commissions oncology services from several Welsh health boards and English provider organisations. Unfortunately, providers do not currently

routinely link the drugs that they use to the indication for treatment. The health board is working closely with providers to ensure that this information can be provided in the future. However, due to the quality of the information currently received by the health board, we do not hold the information requested.

Furthermore, we do not initiate any clinical trials within our health board and we do not hold records of patients on clinical trials initiated by external providers.

We therefore recommend that our providers are approached directly:

Health Board/Organisation (Wales)	FOI Contact Details
Aneurin Bevan University Health Board	FOI.ABB@wales.nhs.uk
Betsi Cadwaladr University Health Board	bcu.foi@wales.nhs.uk
Cardiff & Vale University Health Board	FOI.Requests@wales.nhs.uk
Cwm Taf Morgannwg University Health Board	Freedomofinformation@wales.nhs.uk
Hywel Dda University Health Board	FOI.hyweldda@wales.nhs.uk
Swansea Bay University Health Board	FOIA.Requests@wales.nhs.uk
Velindre University Health Board	Foi.vunhst@wales.nhs.uk

NHS Provider (England)	FOI Contact Details
Gloucester Hospitals NHS Foundation Trust	ghn-tr.foi@nhs.net
Midlands Partnership NHS Foundation Trust	FOI@mpft.nhs.uk
Sandwell and West Birmingham NHS Trust	swb-tr.SWBH-GM-FOIRequests@nhs.net
Shrewsbury and Telford Hospital NHS Trust	https://www.sath.nhs.uk/about-us/freedom-of-information/make-an-enquiry/
The Royal Wolverhampton NHS Trust	rwh-tr.foi@nhs.net
Worcestershire Acute Hospitals NHS Trust	wah-tr.FOI@nhs.net
Wye Valley NHS Trust	Freedom.information@WVT.nhs.uk

Should you need any further assistance, please do not hesitate to contact me at the address below.

If you are dissatisfied, with the way your request has been dealt with by PTHB, you have the right to request a review in which case you should write to:


Chief Executive
Powys Teaching Health Board Headquarters
Glasbury House
Bronllys Hospital
Bronllys
Brecon
Powys LD3 0LY

If you are still dissatisfied at the end of the review, you may complain to the Information Commissioner, who can be contacted at the following address:

Information Commissioner's Office - Wales
2nd Floor,
Churchill House,
Churchill Way,
Cardiff, CF10 2HH
Tel: 029 2067 8400 Fax 029 2067 8399
www.ico.org.uk twitter.com/iconews

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi. We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.

Yours sincerely



Assistant Medical Director